CareDx shares have doubled in 2026. Will July 30 earnings support the surge?
CareDx reports Q2 results on July 30 as investors assess transplant testing growth, Medicare coverage clarity and the Naveris strategy.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Exact Sciences unveils key Oncodetect results in TNBC: Is this a reimbursement turning point?
Exact Sciences Corporation has presented first-time clinical results for its Oncodetect molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC), showcasing a strong correlation between circulating tumor DNA (ctDNA) detection and recurrence risk following neoadjuvant therapy and surgery. The results, drawn from a 147-patient cohort in the NSABP B-59 substudy, were unveiled at